Determinants of paclitaxel penetration and accumulation in human solid tumor

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 871-880

  Kuh, Hyo Jeong ^a,b   Jang, Seong H ^a   Wientjes, M Guillaume ^a   Weaver, Jean R ^a   Au, Jessie L S ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b The Catholic University of Korea   (South Korea)

^c College of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CELL CULTURE; CELL DENSITY; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTORADIOGRAPHY; CULTURE TECHNIQUES; DIFFUSION; FEMALE; HALF-LIFE; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL; PHARYNGEAL NEOPLASMS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032789521     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Au JLS, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh, HJ, Chen, CT and Wientjes MG (1998) Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention. Cancer Res 58:2141-2148.
2. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G and Willingham MC (1994) Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8:465-475.
3. Derry WB, Wilson L and Jordan MA (1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34:2203-2211.
4. Durand RE (1989) Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst 81:146-152.
5. Durand RE (1990) Slow penetration of anthracyclines into spheroids and tumors: A therapeutical advantage? Cancer Chemother Pharmacol 26:198-204.
6. Erlanson M, Daniel-Szolgay E and Carlsson J (1992) Relationship between the penetration, binding and average concentration of cytostatic drug in human tumor spheroids. Cancer Chemother Pharmacol 29:343-353.
7. Fox JR and Wayland H (1979) Interstitial diffusion of macromolecules in the rat mesentery. Microvasc Res 18:255-276.
8. Furukawa T, Kubota T and Hoffman RM (1995) The clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305-311.
9. Gan Y, Wientjes MG and Au JLS (1998) Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res 4:2949-2955.
10. Gan Y, Wientjes MG, Schuller DE and Au JLS (1996) Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 66:2086-2093.
11. Jang SH, Kuh HJ, Wientjes MG and Au JLS (1998) Kinetics and mathematical modeling of paclitaxel efflux by P-glycoprotein in BC19 cells. Proc Am Assoc Cancer Res 39:218.
12. Jekunen AP, Christen RD, Shalinsky DR and Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306.
13. Jordan MA, Toso RJ, Thrower D and Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552-9556.
14. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825.
15. Kang HJK., Tran AQ, Wientjes MG and Au JLS (1997) A kinetic model for taxol accumulation in human cancer cells: In vivo extrapolation. Proc Am Assoc Cancer Res 38:604.
16. Kearns CM, Gianni L and Egorin MJ (1995) Faclitaxel pharmacokinetics and pharmacodynamics. Sem Oncol 22(Suppl 6):16-23.
17. Kleinman H (1990) Extracellular matrix regulation of growth and gene expression. Proc Am Assoc Cancer Res 31:490-491.
18. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, Hoffman R and the Chemosensitivity Study Group for the Histoculture Drug-Response Assay (1995) Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543.
19. 3H]paclitaxel in rats: A quantitative autoradiographic study. Cancer Chemother Pharmacol 37:173-178.
20. Lopes NM, Adams EG, Pitts TW and Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242.
21. Manfredi JJ, Parness J and Horwitz SB (1982) Taxol binda to cellular microtubules. J Cell Biol 94:688-696.
22. Nederman T and Carlsson J (1984) Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13:131-135.
23. Nederman T, Carlsson J and Kuoppa K (1988) Penetration of substances into tumor tissue - Model studies using saccharides, thymidine and thymidine-5′-triphosphate in cellular spheroids. Cancer Chemother Pharmacol 22:21-25.
24. Nederman T, Carlsson J and Malmqvist M (1981) Penetration of substances into tumor tissue: A methodological study on cellular spheroids. In Vitro 17:290-298.
25. Nicholson KM, Bibby MC and Phillips RM (1997) Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 33: 1291-1298.
26. Parness J and Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479-487.
27. Pavelic ZP, Reising J, Pavelic L, Kelley DJ, Stambrook PJ and Gluckman JL (1993) Detection of p-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch Otolaryngol Head Neck Surg 119:753-757.
28. Ringel I and Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 242:692-698.
29. Riou JF, Retitgenet O, Combeau C and Lavelle F (1994) Cellular uptake and efflux of docetaxel (taxotere) and paclitaxel (taxol) in P388 cell line. Proc Am Assoc Cancer Res 35:160.
30. Robbins KT, Connors KM, Storniolo AM, Hanchett C and Hoffman RM (1994) Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch Otolaryngol Head Neck Surg 120:288-292.
31. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ and Donehower RC (1993) Taxol: Pharmacology, metabolism and clinical implications. Cancer Surveys 17:283-301.
32. Roy S and Horwitz SB (1985) A phosphoglycoprotein associated with taxol-resistance in J774.2 cells. Cancer Res 45:3856-3865.
33. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M and Monsarrat B (1995) Paclitaxel metabolites in human plasma and urine: Identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/ atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 9:495-502.
34. Saunders DE, Lawrence WD, Christensen C, Wappler ML, Ruan H and Deppe G (1997) Paclitaxel-induced apoptosis in MCF7 breast cancer cells. Int J Cancer 70:214-220.
35. Schinkel AH, Roelofs MEM, and Borst P (1991) Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 51:2628-2635.
36. Schultz JS and Armstrong W (1978) Permeability of interstitial space of muscle (rat diaphragm) to solutes of different molecular weights. J Pharm Sci 67:696-700.
37. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD and Tew KD (1994) P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine. J Natl Cancer Inst 88:688-694.
38. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM and Rustum YM (1994) New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 144:227-236.